Align Technology Faces Revenue Challenges Amid iTero Growth

The digital smile takes a sharp turn. Align Technology just gave us a third-quarter report that’s all about conflicting signals. Doctor adoption of their clear aligners keeps climbing. Yet the money coming in per case keeps dropping. Their iTero scanner business is seeing more machines installed in offices than ever before. Yet revenue from that very division is falling. This is the puzzle facing Align, and it’s why my view on the stock has shifted. After this earnings call, I’m moving my rating from Buy to Hold. The stock now sits near what I see as its fair value of $150 per share.

You have to look at the two sides of Align’s business separately to understand the strain. Start with their core clear aligner segment. Volume is not the problem. The company shipped over 700,000 cases last quarter, a clear sign that orthodontists and dentists continue to embrace the Invisalign system. That’s a powerful testament to their brand strength and clinical results. But here’s the catch. The average revenue Align books for each of those cases is softening. This isn’t a new trend but the pressure is persistent. Doctors are increasingly opting for more affordable case packages like the Invisalign Go product for less complex treatments. This mix shift directly hits the top line.

Now, look at the scanner business. On the surface, the news seems fantastic. Align placed over 5,500 new iTero scanners in clinics last quarter. That’s a record number for a third quarter. More scanners in the field should mean more scans, more data, and a tighter integration with the Invisalign workflow. But that’s not translating into scanner revenue growth. In fact, scanner revenue declined year-over-year. Why? The model is changing. Clinics are increasingly choosing to rent scanners rather than buy them outright. They’re also selecting lower-cost models. This means Align books less cash upfront, spreading the revenue over a longer subscription period. It’s a strategic move to deepen market penetration but it immediately depresses the division’s sales figures.

These trends point to a broader competitive landscape that’s getting tougher. Align no longer has the clear aligner market to itself. Competitors like SmileDirectClub may have faded but a host of other players including dental lab networks and regional providers are offering lower-priced alternatives. Doctors feel this price pressure from their own patients and are responding by seeking value. Furthermore, in the massive China market, the game is different altogether. There, the government’s Volume-Based Procurement (VBP) program centralizes purchasing. This essentially turns the process into a bidding war, forcing suppliers like Align to compete aggressively on price to secure contracts with public hospitals. It’s a structural headwind that caps pricing power in a critical growth region.

The financial picture that emerges is one of a company being squeezed on both ends. Total revenue growth has slowed to a mid-single-digit pace. Operating margins are feeling the pinch from these pricing dynamics even as Align works hard to control costs. There are bright spots of course. The company remains a cash-generating machine. They ended the quarter with over $900 million in cash and short-term investments. They continue to buy back shares aggressively, a program that directly supports earnings per share. But share repurchases are a financial engineering tool not a growth catalyst. They don’t fix the underlying business momentum.

So where does this leave investors? The bull case rests on Align’s unmatched scale, its vast doctor network, and the long-term potential of all those iTero scanners driving case volume. The bear case focuses on the unrelenting pricing pressure and the lack of a near-term driver to reaccelerate revenue growth meaningfully. At the current share price, the market seems to be balancing these forces fairly. The valuation no longer discounts a high-growth trajectory but it doesn’t assume a decline either. It prices in a company that is maturing, facing realistic competitive pressures, and managing for steady profitability. That’s a Hold scenario.

Watching Align now is about watching for a shift in these key metrics. Can they stabilize the decline in average revenue per case? Will the scanner rental model eventually lead to a more predictable, high-margin recurring revenue stream? Can they outperform in markets outside of China’s VBP system? Until we see convincing evidence on these fronts, the stock is likely to trade in a range. The easy money from the post-pandemic recovery boom is gone. What’s left is the hard work of executing in a more challenging market. For now, I see better opportunities elsewhere.

• Doctor adoption of clear aligners keeps climbing
• Revenue per case is dropping
• Over 700,000 cases shipped last quarter
• Over 5,500 new iTero scanners placed
• Revenue from scanners is declining
• Increased competition in the market